Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Nucl Med Biol. 2012 Mar 22;39(7):926–932. doi: 10.1016/j.nucmedbio.2012.01.010

Table 1.

Clinical data and alpha-[11C]methyl-L-tryptophan (AMT) PET kinetic values of the 9 patients with breast cancer. Patients are listed from the lowest to the highest AMT standardized uptake values (SUV).

Patient age
(years)		 Tumor type Tumor
grade		 Tumor
stage		 ER PR HER2/
neu		 VD’ K1
ml/g/min		 SUV
1. 63 carcinosarcoma I IIIB − − − 0.74 0.14 2.6
2. 57 invasive microp. cc. III IV + + − 1.07 0.13 3.1
3. 50 carcinosarcoma III IIIA − − − 1.13 0.17 4.2
4. 29 invasive ductal cc. III IIIA + + +++ 1.23 0.22 4.7
5. 59 invasive ductal cc. II IIA − + +++ 1.52 0.23 5.0
6. 56 invasive ductal cc. II IIIA − − − 1.32 0.21 5.2
7. 33 invasive ductal cc. III IIIA − + − 1.45 0.21 6.5
8. 60 invasive ductal cc. III IIIB − + − 2.01 0.12 6.6*
9. 44 invasive ductal cc.† III IV + + − 1.61 0.23 9.8*

Abbreviations: microp.: micropapillary; cc: carcinoma; ER: estrogen receptors; PR: progesterone receptors; VD’: volume of distribution on PET; SUV: standardized uptake values;

†

patient with extensive metastases (brain, lung, liver, bone);

*

patients with prolonged (>20 min) AMT accumulation in tumor